Fax: (817) 759-7030
Dose-dense vinorelbine and docetaxel with Filgrastim support in patients with advanced nonsmall cell lung carcinoma†
Article first published online: 21 SEP 2005
Copyright © 2005 American Cancer Society
Volume 104, Issue 9, pages 1956–1961, 1 November 2005
How to Cite
Page, R. D., Smith, F. P., Geils, G. F., Beall, C. L., Fridman, M. and Allen, B. J. (2005), Dose-dense vinorelbine and docetaxel with Filgrastim support in patients with advanced nonsmall cell lung carcinoma. Cancer, 104: 1956–1961. doi: 10.1002/cncr.21400
Presented at the 40th annual meeting of the American Society of Clinical Oncology, New Orleans, Louisiana, June 5–8, 2004.
- Issue published online: 17 OCT 2005
- Article first published online: 21 SEP 2005
- Manuscript Accepted: 16 MAY 2005
- Manuscript Revised: 25 APR 2005
- Manuscript Received: 2 FEB 2005
- Amgen Inc., Thousand Oaks, CA
- 2http://cancernetwork.com/textbook/morev12.htm (accessed November 2, 2004)., , . Non-small cell lung cancer. In: Medical oncology: a comprehensive review. Available from URL:
- 4Current paradigms in first-line treatment of non-small-cell lung cancer. Oncology. 2004; 18(Suppl): 13–20..
- 5In vitro combination effect of docetaxel (RP56976) with vinca alkaloids on cancer cell line [abstract 1780]. Proc Am Assoc Cancer Res. 1995; 36: 299., , , et al.
- 6Synergistic effect of docetaxel (DCT) and vinorelbine (VNB) against in vitro growth of a human small-cell lung cancer line [abstract 2560]. Proc Am Assoc Cancer Res. 1996; 37: 375., , , et al.
- 16Advances in lung cancer therapy. Toxicol Pathol. 2003; 31: 147–148..
- 18Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003; 21: 1431–1439., , , et al.
- 21Medical Research Council Lung Cancer Working Party. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. J Clin Oncol. 2000; 18: 395–404., , , , , , for the